Home - Australian Pharmacist

DAA program to be expanded in community pharmacies

Sharon Smith - June 18, 2018

Industry

The Dose Administration Aids (DAA) program will be available to 70,000 more patients each year through community pharmacies, with the Federal Government announcing increased...

E-cigarettes warning after link with pulmonary illness in US

Raveena Grover - September 18, 2019

Industry

A new statement on e-cigarettes has been issued by the Australian Government Department of Health. The Australian Government Department of Health has issued a new...

Leading Pharmacy Future: PSA18 highlights

James Chalmers - July 24, 2018

PSA18 text in a circle with multicoloured light reflections

Events

Sydney will become the centre of the Australian pharmacy universe on Friday, as PSA18 brings together more than 1000 pharmacists and healthcare leaders for...

Catastrophic fire ratings highlight need for better emergency dispensing provisions

Jennifer Cooke - November 13, 2019

Industry

State and federal health departments have advised of options available to pharmacists in parts of NSW and Queensland affected by this week’s catastrophic-level fires. Under...

COVID-19 death toll passes 2000

Ruth Cooper - February 19, 2020

A scanning electron microscope image shows SARS-CoV-2 (yellow) – also known as 2019-nCoV, the virus that causes COVID-19 –isolated from a patient in the US, emerging from the surface of cells (blue/pink) cultured in a lab. Image: NIAID-RML

Industry

The federal government will provide $2 million to help develop a vaccine for COVID-19, as the death toll from the novel coronavirus continues to climb.

If catastrophe calls, include these ‘musts’ in your plan

Emmanuel Pasura MPS - February 25, 2020

People

It’s imperative that every pharmacy have a disaster plan, a clear written procedure on what to do, to eliminate delays getting deliveries to affected areas.

1...275276277...318 Page 276 of 318

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

Case scenario

Learning objectives

Introduction

Epidemiology

Aetiology and pathophysiology

Risk factors

Clinical features

Management

Knowledge to practice

Case scenario continued

Key points

References

Our author

Our reviewer

1. Therapeutic Guidelines overhaul UTI treatment

2. Is Rikodeine still being rescheduled?

What else was popular?

1. PBS co‑payment will drop

2. Transition to the new MMR credential must be completed

3. Continued freeze on PBS concessional co‑payment

4. Optional allowable discount phase out continues

5. New PSA standards for CPD accreditation launch

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

So what about the Rikodeine?

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines

References

Case scenario

Learning objectives

Introduction

Epidemiology

Aetiology and pathophysiology

Risk factors

Clinical features

Management

Knowledge to practice

Case scenario continued

Key points

References

Our author

Our reviewer

1. Therapeutic Guidelines overhaul UTI treatment

2. Is Rikodeine still being rescheduled?

What else was popular?

1. PBS co‑payment will drop

2. Transition to the new MMR credential must be completed

3. Continued freeze on PBS concessional co‑payment

4. Optional allowable discount phase out continues

5. New PSA standards for CPD accreditation launch

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

So what about the Rikodeine?

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines

References

Case scenario

Learning objectives

Introduction

Epidemiology

Aetiology and pathophysiology

Risk factors

Clinical features

Management

Knowledge to practice

Case scenario continued

Key points

References

Our author

Our reviewer

1. Therapeutic Guidelines overhaul UTI treatment

2. Is Rikodeine still being rescheduled?

What else was popular?

1. PBS co‑payment will drop

2. Transition to the new MMR credential must be completed

3. Continued freeze on PBS concessional co‑payment

4. Optional allowable discount phase out continues

5. New PSA standards for CPD accreditation launch